Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach

Bhatnager, Richa; Bhasin, Maheshwar; Arora, Jyoti; Dang, Amita Suneja

doi:10.1080/07391102.2020.1787227

Cited by 56 publications

(40 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from this, b-defensin interact with the immune receptors such as TLRs or CCR6 and induces innate and adaptive immune responses (Lei et al, 2019). It is used as an adjuvant in the construction of several vaccines by Immunoinformatics approach (Ali et al, 2017;Bhatnager et al, 2020;Dong et al, 2020;Narula et al, 2018). Apart from b-defensin, PADRE (pan DR epitope) sequence was also included in the vaccine construct to increase the immunogenicity of the vaccine construct as well as to enhance the T-cell help (Alexander et al, 2000;Sarkar et al, 2020;Wu et al, 2010).…”

Section: Design Of Vaccine Constructmentioning

confidence: 99%

“…The whole genome sequence of the SARS-CoV2 is made available in the public domain by next generation sequencing. This enabled the design of several multi-epitope in silico vaccine candidates targeting different structural and nonstructural proteins of the SARS-CoV2 (Bhatnager et al, 2020;Bhattacharya et al, 2020;Devi & Chaitanya, 2020;Dong et al, 2020;Enayatkhani et al, 2020;Kar et al, 2020;Lizbeth et al, 2020;Peele et al, 2020;Samad et al, 2020). In the present study, we aimed to design a novel multi-epitope vaccine targeting membrane glycoprotein by immunoinformatics approach.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach

Ayyagari

Venkateswarulu

et al. 2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

In the present study, one of the targets present on the envelopes of coronaviruses, membrane glycoprotein (M) was chosen for the design of a multi-epitope vaccine by Immunoinformatics approach. The B-cell and T-cell epitopes used for the construction of vaccine were antigenic, nonallergic and nontoxic. An adjuvant, b-defensin and PADRE sequence were included at the N-terminal end of the vaccine. All the epitopes were joined by linkers for decreasing the junctional immunogenicity. Various physicochemical parameters of the vaccine were evaluated. Secondary and tertiary structures were predicted for the vaccine construct. The tertiary structure was further refined, and various parameters related to the refinement of the protein structure were validated by using different tools. Humoral immunity induced by B-cells relies upon the identification of antigenic determinants on the surface of the vaccine construct. In this regard, the vaccine construct was found to consist of several B-cell epitopes in its three-dimensional conformation. Molecular docking of the vaccine was carried out with TLR-3 receptor to study their binding and its strength. Further, protein-protein interactions in the docked complex were visualized using LigPlotþ. Population coverage analysis had shown that the multi-epitope vaccine covers 94.06% of the global population. The vaccine construct was successfully cloned in silico into pET-28a (þ). Immune simulation studies showed the induction of primary, secondary and tertiary immune responses marked by the increased levels of antibodies, INF-c, IL-2, TGF-b, B-cells, CD4þ and CD8þ cells. Finally, the vaccine construct was able to elicit immune response as desired.

show abstract

Section: Design Of Vaccine Constructmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach

Ayyagari

Venkateswarulu

et al. 2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

show abstract

“…105,106 These three TLRs were used in designing in previous bioinformatic-based vaccines against SARS-CoV-2. 30,107,108 The results of docking analysis showed the vaccine protein properly interacts with TLR3, 5, and 8. In addition, docking results of the vaccine and ACE-2 reveal the RBD epitopes of the vaccine can efficiently interact with ACE-2.…”

Section: Dovepressmentioning

confidence: 99%

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Yazdani¹,

Rafiei²,

Yazdani³

et al. 2020

IDR

View full text Add to dashboard Cite

Background: To date, no specific vaccine or drug has been proven to be effective against SARS-CoV-2 infection. Therefore, we implemented an immunoinformatic approach to design an efficient multi-epitopes vaccine against SARS-CoV-2. Results: The designed-vaccine construct consists of several immunodominant epitopes from structural proteins of spike, nucleocapsid, membrane, and envelope. These peptides promote cellular and humoral immunity and interferon-gamma responses. Also, these epitopes have a high antigenic capacity and are not likely to cause allergies. To enhance the vaccine immunogenicity, we used three potent adjuvants: Flagellin of Salmonella enterica subsp. enterica serovar Dublin, a driven peptide from high mobility group box 1 as HP-91, and human beta-defensin 3 protein. The physicochemical and immunological properties of the vaccine structure were evaluated. The tertiary structure of the vaccine protein was predicted and refined by Phyre2 and Galaxi refine and validated using RAMPAGE and ERRAT. Results of ElliPro showed 246 sresidues from vaccine might be conformational B-cell epitopes. Docking of the vaccine with toll-like receptors (TLR) 3, 5, 8, and angiotensinconverting enzyme 2 approved an appropriate interaction between the vaccine and receptors. Prediction of mRNA secondary structure and in silico cloning demonstrated that the vaccine can be efficiently expressed in Escherichia coli. Conclusion: Our results demonstrated that the multi-epitope vaccine might be potentially antigenic and induce humoral and cellular immune responses against SARS-CoV-2. This vaccine can interact appropriately with the TLR3, 5, and 8. Also, it has a high-quality structure and suitable characteristics such as high stability and potential for expression in Escherichia coli .

show abstract

“… 12 Recent efforts for designing epitope-based peptide vaccine based on an immune-informatics approach showed that a multivalent subunit vaccine targeting S2 subunit of SARS-CoV-2 S glycoprotein might have potential to activate innate and adaptive immune responses. 13 In addition, the receptor binding domain (RBD) of the S protein of SARS-CoV-2 appears to be potentially useful in the serological diagnostic assays for COVID-19 patients. 14 Furthermore, the immune responses to S-RBD binding antibodies exhibited a correlation with neutralizing capacity, suggesting a potential COVID-19 immunity.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis

et al. 2020

View full text Add to dashboard Cite

Background: Observational studies of the ongoing coronavirus disease 2019 (COVID-19) outbreak suggest that a 'cytokine storm' is involved in the pathogenesis of severe illness. However, the molecular mechanisms underlying the altered pathological inflammation in COVID-19 are largely unknown. We report here that toll-like receptor (TLR) 4-mediated inflammatory signaling molecules are upregulated in peripheral blood mononuclear cells (PBMCs) from COVID-19 patients, compared with healthy controls (HC). Methods: A total of 48 subjects including 28 COVID-19 patients (8 severe/critical vs. 20 mild/ moderate cases) admitted to Chungnam National University Hospital, and age/sex-matched 20 HC were enrolled in this study. PBMCs from the subjects were processed for nCounter Human Immunology gene expression assay to analyze the immune related transcriptome profiles. Recombinant proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were used to stimulate the PBMCs and monocyte-derived macrophages, and real-time polymerase chain reaction was performed to quantify the mRNA expressions of the proinflammatory cytokines/chemokines. Results: Among the most highly increased inflammatory mediators in severe/critically ill patients, S100A9, an alarmin and TLR4 ligand, was found as a noteworthy biomarker, because it inversely correlated with the serum albumin levels. We also observed that recombinant S2 and nucleocapsid proteins of SARS-CoV-2 significantly increased proinflammatory cytokines/chemokines and S100A9 in human primary PBMCs. Conclusion: These data support a link between TLR4 signaling and pathological inflammation during COVID-19 and contribute to develop therapeutic approaches through targeting TLR4-mediated inflammation.

show abstract

Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach

Cited by 56 publications

References 44 publications

Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach

Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis

Contact Info

Product

Resources

About